scholarly journals Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.

1996 ◽  
Vol 93 (15) ◽  
pp. 7944-7949 ◽  
Author(s):  
G. Renauld-Mongenie ◽  
N. Mielcarek ◽  
J. Cornette ◽  
A. M. Schacht ◽  
A. Capron ◽  
...  
1995 ◽  
Vol 25 (4) ◽  
pp. 969-975 ◽  
Author(s):  
Jim Vadolas ◽  
John K. Davies ◽  
Peter J. Wright ◽  
Richard A. Strugnell

Vaccine ◽  
2012 ◽  
Vol 30 (52) ◽  
pp. 7541-7546 ◽  
Author(s):  
Armando Stano ◽  
Chiara Nembrini ◽  
Melody A. Swartz ◽  
Jeffrey A. Hubbell ◽  
Eleonora Simeoni

2017 ◽  
Vol 187 ◽  
pp. 41-46 ◽  
Author(s):  
Jingcai Lu ◽  
Hongjia Hou ◽  
Dandan Wang ◽  
Kees Leenhouts ◽  
Maarten L.van Roosmalen ◽  
...  

Vaccine ◽  
2000 ◽  
Vol 18 (21) ◽  
pp. 2203-2211 ◽  
Author(s):  
Maria E. Baca-Estrada ◽  
Marianna Foldvari ◽  
Marlene Snider ◽  
Kent Harding ◽  
Bill Kournikakis ◽  
...  

2005 ◽  
Vol 73 (7) ◽  
pp. 4295-4301 ◽  
Author(s):  
Sylvie Alonso ◽  
Eve Willery ◽  
Genevieve Renauld-Mongénie ◽  
Camille Locht

ABSTRACT Bordetella pertussis, the etiologic agent of whooping cough, is a highly infectious human pathogen capable of inducing mucosal and systemic immune responses upon a single intranasal administration. In an attenuated, pertussis toxin (PTX)-deficient recombinant form, it may therefore constitute an efficient bacterial vector that is particularly well adapted for the delivery of heterologous antigens to the respiratory mucosa. Filamentous hemagglutinin (FHA) has been used as a carrier to present foreign antigens at the bacterial surface, thereby inducing local, systemic, and protective immune responses to these antigens in mice. Both full-length and truncated (Fha44) forms of FHA have been used for antigen presentation. To investigate the effect of the carrier (FHA or Fha44) on antibody responses to passenger antigens, we genetically fused the HtrA protein of nontypeable Haemophilus influenzae to either FHA form. The fha-htrA and Fha44 gene-htrA hybrids were expressed as single copies inserted into the chromosome of PTX-deficient B. pertussis. Both chimeras were secreted into the culture supernatants of the recombinant strains and were recognized by anti-FHA and anti-HtrA antibodies. Intranasal infection with the strain producing the FHA-HtrA hybrid led to significantly higher anti-HtrA and anti-FHA antibody titers than those obtained in mice infected with the Fha44-HtrA-producing strain. Interestingly, the B. pertussis strain producing the Fha44-HtrA chimera colonized the mouse lungs more efficiently than the parental, Fha44-producing strain and gave rise to higher anti-FHA antibody titers than those induced by the parental strain.


npj Vaccines ◽  
2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Dylan T. Boehm ◽  
M. Allison Wolf ◽  
Jesse M. Hall ◽  
Ting Y. Wong ◽  
Emel Sen-Kilic ◽  
...  

Abstract Current acellular pertussis vaccines fall short of optimal protection against the human respiratory pathogen Bordetella pertussis resulting in increased incidence of a previously controlled vaccine- preventable disease. Natural infection is known to induce a protective mucosal immunity. Therefore, in this study, we aimed to use acellular pertussis vaccines to recapitulate these mucosal immune responses. We utilized a murine immunization and challenge model to characterize the efficacy of intranasal immunization (IN) with DTaP vaccine or DTaP vaccine supplemented with curdlan, a known Th1/Th17 promoting adjuvant. Protection from IN delivered DTaP was compared to protection mediated by intraperitoneal injection of DTaP and whole-cell pertussis vaccines. We tracked fluorescently labeled DTaP after immunization and detected that DTaP localized preferentially in the lungs while DTaP with curdlan was predominantly in the nasal turbinates. IN immunization with DTaP, with or without curdlan adjuvant, resulted in anti-B. pertussis and anti-pertussis toxin IgG titers at the same level as intraperitoneally administered DTaP. IN immunization was able to protect against B. pertussis challenge and we observed decreased pulmonary pro-inflammatory cytokines, neutrophil infiltrates in the lung, and bacterial burden in the upper and lower respiratory tract at day 3 post challenge. Furthermore, IN immunization with DTaP triggered mucosal immune responses such as production of B. pertussis-specific IgA, and increased IL-17A. Together, the induction of a mucosal immune response and humoral antibody-mediated protection associated with an IN administered DTaP and curdlan adjuvant warrant further exploration as a pertussis vaccine candidate formulation.


Sign in / Sign up

Export Citation Format

Share Document